Search Results

While ex vivo genome editing results in highly effective cell therapies, it can lead to off-target effects. Caribou Biosciences has come up with a novel approach for potentially more precise gene editing compared to all-RNA guides.

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced that it had granted Caribou Biosciences, Inc., a leading CRISPR genome-editing cell therapy company, a non-exclusive, worldwide license, with the right to sublicense, to one of Precision’s foundational cell therapy patent families for use with CRISPR in the field of human therapeutics.

Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

Soon after cancelling its contract with I-Mab, AbbVie has now also turned its back on a partnership with Berkeley-based Caribou Biosciences that was focused on advancing allogeneic CAR-T therapeutics.

Discovery Therapeutics Caribe (DTC), a clinical-stage biotechnology company dedicated to improving the health outcomes of Americans through the development of regenerative therapies for serious and life-threatening diseases, today announced it has achieved a significant milestone reflecting progress in its clinical program.

Xenetic Biosciences, Inc. today announced the appointment of James Parslow, the Company’s Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024.